NCT01730612View on ClinicalTrials.gov

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

HER2 Negative Breast Carcinoma Expressing CEA

Interventions

DRUG

TF2 - 68 Ga-IMP-288:

ImmunoTEP

Trial Locations (2)

44093

Hospital, Nantes

44805

Institut de Cancérologie de l'Ouest, Saint-Herblain

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Gilead Sciences

INDUSTRY

lead

Nantes University Hospital

OTHER

NCT01730612 - ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA | Biotech Hunter | Biotech Hunter